Hema K Alajangi
Overview
Explore the profile of Hema K Alajangi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thakur A, Alajangi H, Sharma A, Hwang E, Khajuria A, Kumari L, et al.
Discov Nano
. 2025 Mar;
20(1):50.
PMID: 40063147
In light of growing global challenge posed by antimicrobial resistance, it is very important to explore alternatives that can target pathogenic microorganisms. One such strategy involves the use of antimicrobial...
2.
Suresh Babu A, Sharma A, Athira M, Alajangi H, Raj A, Gartia J, et al.
Sci Rep
. 2025 Mar;
15(1):7901.
PMID: 40050320
No abstract available.
3.
Khajuria A, Alajangi H, Sharma A, Kaur H, Sharma P, Negi S, et al.
Discov Nano
. 2024 Sep;
19(1):145.
PMID: 39256285
Breast cancer is one of the leading causes of death among women globally, making its diagnosis and treatment challenging. The use of nanotechnology for cancer diagnosis and treatment is an...
4.
Rani S, Dey P, Pruthi K, Singh S, Mahajan S, Alajangi H, et al.
Crit Rev Ther Drug Carrier Syst
. 2024 Apr;
41(5):65-110.
PMID: 38608133
Cosmeceuticals have gained great importance and are among the top-selling products used for skin care. Because of changing lifestyles, climate, and increasing pollution, cosmeceuticals are utilized by every individual, thereby...
5.
A Path of Novelty from Nanoparticles to Nanobots: Theragnostic Approach for Targeting Cancer Therapy
Kaur G, Khanna B, Yusuf M, Sharma A, Khajuria A, Alajangi H, et al.
Crit Rev Ther Drug Carrier Syst
. 2024 Feb;
41(4):1-38.
PMID: 38305340
Pharmaceutical development of cancer therapeutics is a dynamic area of research. Even after decades of intensive work, cancer continues to be a dreadful disease with an ever-increasing global incidence. The...
6.
Suresh Babu A, Sharma A, Athira M, Alajangi H, Raj A, Gartia J, et al.
Sci Rep
. 2023 Sep;
13(1):15289.
PMID: 37714933
The current work involves the use of dehydroacetic acid based chalcone derivatives for the synthesis of spirooxindole grafted pyrrolidine moieties. All the synthesized compounds have been characterized using spectroscopic techniques...
7.
Chamoli T, Khera A, Sharma A, Gupta A, Garg S, Mamgain K, et al.
Heliyon
. 2023 Jan;
8(12):e12283.
PMID: 36590540
Proteins are essential building blocks in humans that have garnered huge attention from researchers worldwide due to their numerous therapeutic applications. To date, different computational tools have been developed to...
8.
Kaur P, Khera A, Alajangi H, Sharma A, Jaiswal P, Singh G, et al.
Mol Neurobiol
. 2022 Dec;
60(3):1690-1720.
PMID: 36562884
A few protein kinases and phosphatases regulate tau protein phosphorylation and an imbalance in their enzyme activity results in tau hyper-phosphorylation. Aberrant tau phosphorylation causes tau to dissociate from the...
9.
Thakur A, Sharma A, Alajangi H, Jaiswal P, Lim Y, Singh G, et al.
Int J Biol Macromol
. 2022 Jul;
218:135-156.
PMID: 35868409
Antimicrobial peptides (AMPs) attracted attention as potential source of novel antimicrobials. Multi-drug resistant (MDR) infections have emerged as a global threat to public health in recent years. Furthermore, due to...
10.
Khera A, Alajangi H, Khajuria A, Barnwal R, Kumar S, Singh G
Curr Drug Deliv
. 2022 Apr;
20(4):317-334.
PMID: 35379150
Breast cancer, being the second most common type of cancer, is a leading cause of death in the female population. Of all the available treatments existing for breast cancer, exosomes...